Skip to main content
Clinical Trials/NL-OMON53411
NL-OMON53411
Completed
Not Applicable

A Multicenter, Cross-sectional Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD) - 20210057

Amgen0 sites1,500 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atherosclerosis
Sponsor
Amgen
Enrollment
1500
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
April 28, 2023
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Amgen

Eligibility Criteria

Inclusion Criteria

  • 101\. Subject has provided informed consent prior to initiation of any study
  • specific activities/procedures.
  • 102\. Age 18 to 85 years.
  • 103\. History of ASCVD as demonstrated by either:
  • a) MI (presumed type 1\)
  • b) PCI (with high\-risk features) with at least 1 of the following:
  • \- Age \> 65 years
  • \-Diabetes mellitus
  • \- History of ischemic stroke
  • \- History of peripheral arterial disease

Exclusion Criteria

  • 201\. Subjects known to be currently receiving investigational drug in a
  • clinical study that is anticipated to last \> 1 year
  • 202\. Known Lp(a) value \< 90 mg/dL (if measured in mass) or \< 200 nmol/L (if
  • measured in molar).
  • 203\. Subject has a diagnosis of end\-stage renal disease or requires dialysis
  • 204\. Poorly controlled (glycated hemoglobin \[HbA1c] \> 10%) diabetes mellitus
  • (type 1 or type 2\).
  • 205\. Subject is receiving or has received lipoprotein apheresis to reduce Lp(a)
  • within 3 months prior to enrollment.
  • 206\. Known uncontrolled or recurrent ventricular tachycardia in the past 3

Outcomes

Primary Outcomes

Not specified

Similar Trials